Rosuvastatin

Lipid-lowering statin whose exposure increased by 41% when combined with oral semaglutide (Wegovy tablets), a change the summary of product characteristics does not consider clinically relevant given its wide therapeutic margin.

Institutional endorsement by Clínica Evolution

This entry is for information. Your case requires an individual medical assessment.